

# Afshin Dowlati

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9353017/afshin-dowlati-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

102  
papers

9,998  
citations

30  
h-index

99  
g-index

108  
ext. papers

12,313  
ext. citations

6.8  
avg, IF

5.6  
L-index

#	Paper	IF	Citations
102	Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.. <i>Lung Cancer</i> , <b>2022</b> , 166, 135-142	5.9	1
101	Novel Non-Invasive Radiomic Signature on CT Scans Predicts Response to Platinum-Based Chemotherapy and Is Prognostic of Overall Survival in Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 744724	5.3	6
100	Stereotactic body radiotherapy (SBRT) for T2N0 (>3 cm) non-small cell lung cancer: Outcomes and failure patterns. <i>Journal of Radiosurgery and SBRT</i> , <b>2021</b> , 7, 271-277	0.4	
99	Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer. <i>Clinical and Translational Science</i> , <b>2021</b> , 14, 664-670	4.9	
98	Role of immunotherapy in gastro-enteropancreatic neuroendocrine neoplasms (gep-nens): Current advances and future directions. <i>Journal of Neuroendocrinology</i> , <b>2021</b> , 33, e12943	3.8	0
97	Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries. <i>Cancer Medicine</i> , <b>2021</b> , 10, 3862-3872	4.8	8
96	A randomized controlled trial of structured palliative care versus standard supportive care for patients enrolled in phase 1 clinical trials. <i>Cancer Medicine</i> , <b>2021</b> , 10, 4312-4321	4.8	2
95	Combination of quantitative features from H&E biopsies and CT scans predicts response to chemotherapy and overall survival in small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 8572-8572	2.2	1
94	Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy. <i>Seminars in Cancer Biology</i> , <b>2021</b> ,	12.7	5
93	Trends in imaging utilization for small cell lung cancer: a decision tree analysis of the NCCN guidelines. <i>Clinical Imaging</i> , <b>2021</b> , 75, 83-89	2.7	0
92	Role of radiation in extensive stage small cell lung cancer: a National Cancer Database registry analysis. <i>Future Oncology</i> , <b>2021</b> , 17, 2713-2724	3.6	1
91	Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2021</b> , 39, 142-151	4.3	3
90	A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours. <i>British Journal of Cancer</i> , <b>2021</b> , 124, 391-398	8.7	2
89	Identification of RUNX1T1 as a potential epigenetic modifier in small-cell lung cancer. <i>Molecular Oncology</i> , <b>2021</b> , 15, 195-209	7.9	6
88	Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , <b>2021</b> , 22, 51-65	21.7	101
87	A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. <i>British Journal of Cancer</i> , <b>2021</b> , 124, 744-753	8.7	23
86	Next Generation Sequencing of Advanced Non-Small Cell Lung Cancer: Utilization Based on Race and Impact on Survival. <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, 16-22.e1	4.9	2

85	LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial. <i>Investigational New Drugs</i> , <b>2021</b> , 39, 1057-1071	4.3	4
84	Genomic analyses of high-grade neuroendocrine gynecological malignancies reveal a unique mutational landscape and therapeutic vulnerabilities. <i>Molecular Oncology</i> , <b>2021</b> , 15, 3545-3558	7.9	0
83	NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. <i>British Journal of Cancer</i> , <b>2021</b> ,	8.7	5
82	A detailed smoking history and determination of status predict response to checkpoint inhibitors in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, 55-60	4.4	13
81	Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 531-540	21.7	279
80	Phase I dose escalation study of immunoconjugate L-DOS47 in combination with pemetrexed/carboplatin in non-squamous non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e21680-e21680	2.2	1
79	Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS9080-TPS9080	2.2	1
78	RESILIENT part II: an open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS9081-TPS9081	2.2	1
77	Imaging features of gastrointestinal toxicity in non-small cell lung cancer patients treated with erlotinib: A single institute 13-year experience. <i>Clinical Imaging</i> , <b>2020</b> , 68, 210-217	2.7	2
76	Role of mTOR As an Essential Kinase in SCLC. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 1522-1534	8.9	4
75	Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. <i>Lancet, The</i> , <b>2019</b> , 394, 1929-1939	40	582
74	A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 738-747	4.3	9
73	Diffuse Atypical Cystic Brain Metastases in ALK+ NSCLC Treated With Whole Brain Radiation and Second-Generation ALK-Targeted Therapy. <i>Practical Radiation Oncology</i> , <b>2019</b> , 9, e129-e133	2.8	1
72	Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. <i>Nature Reviews Cancer</i> , <b>2019</b> , 19, 289-297	31.3	304
71	Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 87-97	4.3	39
70	Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6958-6966	12.9	122
69	First-in-human phase I and pharmacological study of TAS-119, a selective Aurora A (AurA) kinase inhibitor, in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3063-3063	2.2	2
68	Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer. <i>Cancer Medicine</i> , <b>2019</b> , 8, 1459-1466	4.8	24

67	Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial. <i>JAMA Oncology</i> , <b>2019</b> , 5, 351-357	13.4	84
66	Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 210-221	12.9	30
65	Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 731-739	59.2	1285
64	KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e489-e501	4.9	20
63	Relationship between phase I study duration and symptom burden. <i>Supportive Care in Cancer</i> , <b>2018</b> , 26, 731-737	3.9	8
62	Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer. <i>Investigational New Drugs</i> , <b>2018</b> , 36, 435-441	4.3	9
61	Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, 1 <sup>st</sup> line small cell lung cancer: Results from the phase 2 TRINITY study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8507-8507	2.2	40
60	Avelumab in patients with previously treated mesothelioma: Updated phase 1b results from the JAVELIN Solid Tumor trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 166-166	2.2	3
59	Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2386-2394	2.2	162
58	Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma. <i>Molecular Oncology</i> , <b>2018</b> , 12, 2124-2135	7.9	10
57	Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma. <i>Journal of Clinical Pathology</i> , <b>2018</b> , 71, 1108-1115	3.9	21
56	Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance). <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 704-713	8.9	49
55	Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial. <i>JAMA Dermatology</i> , <b>2017</b> , 153, 413-420	5.1	3
54	Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. <i>Cancer Cell</i> , <b>2017</b> , 31, 286-299	24.3	240
53	Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. <i>Lung Cancer</i> , <b>2017</b> , 111, 108-115	5.9	11
52	Prognostic potential of neutrophil-to-lymphocyte ratio and lymphocyte nadir in stage III non-small-cell lung cancer. <i>Future Oncology</i> , <b>2017</b> , 13, 1405-1414	3.6	15
51	RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR. <i>Oncotarget</i> , <b>2017</b> , 8, 5992-6002	3.3	35
50	Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 73745-73756	3.3	65

49	Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer. <i>Reviews on Recent Clinical Trials</i> , <b>2017</b> , 12, 51-58	1.2	1
48	Radiosensitization of non-small-cell lung cancer cells and xenografts by the interactive effects of pemetrexed and methoxyamine. <i>Radiotherapy and Oncology</i> , <b>2016</b> , 121, 335-341	5.3	9
47	Clinical correlation of extensive-stage small-cell lung cancer genomics. <i>Annals of Oncology</i> , <b>2016</b> , 27, 642-7	10.3	48
46	Genomic alterations in small cell lung cancer and their clinical relevance. <i>Translational Lung Cancer Research</i> , <b>2016</b> , 5, 450-1	4.4	3
45	Comparison of cisplatin/etoposide versus carboplatin/etoposide concurrent chemoradiation therapy for limited-stage small cell lung cancer (LS-SCLC) in the elderly population (age >65 years) using national SEER-Medicare data. <i>Practical Radiation Oncology</i> , <b>2016</b> , 6, e163-e169	2.8	7
44	A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 4574-84	12.9	8
43	A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer. <i>Oncologist</i> , <b>2016</b> , 21, 1163-1164	5.7	22
42	CD30 is a potential therapeutic target in malignant mesothelioma. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 740-6	6.1	16
41	Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer. <i>Oncologist</i> , <b>2015</b> , 20, 1298-303	5.7	18
40	PIAS3 expression in squamous cell lung cancer is low and predicts overall survival. <i>Cancer Medicine</i> , <b>2015</b> , 4, 325-32	4.8	18
39	Beyond adenocarcinoma: current treatments and future directions for squamous, small cell, and rare lung cancer histologies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2015</b> , 147-62	7.1	9
38	Low PIAS3 expression in malignant mesothelioma is associated with increased STAT3 activation and poor patient survival. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5124-32	12.9	32
37	Clinical trial design in small cell lung cancer: surrogate end points and statistical evolution. <i>Clinical Lung Cancer</i> , <b>2014</b> , 15, 207-12	4.9	15
36	Pharmacogenomic approach to identify drug sensitivity in small-cell lung cancer. <i>PLoS ONE</i> , <b>2014</b> , 9, e106784	9.7	14
35	PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status. <i>International Journal of Cancer</i> , <b>2014</b> , 134, 1045-54	7.5	11
34	RET mutation and expression in small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 1316-23	8.9	37
33	Phase I Trial of the Base Excision Repair Blocker Methoxyamine (TRC-102) Combined with Fludarabine in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Lymphoid Malignancies. <i>Blood</i> , <b>2014</b> , 124, 4688-4688	2.2	2
32	Combined SCLC clinical and pathologic characteristics. <i>Clinical Lung Cancer</i> , <b>2013</b> , 14, 113-9	4.9	43

31	Phase I expansion study of sunitinib and bevacizumab in patients with advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e13521-e13521	2.2	
30	Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2012</b> , 70, 547-53	3.5	9
29	Final report of an open-label phase II trial of bevacizumab plus docetaxel and gemcitabine in metastatic, previously untreated nonsquamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e18046-e18046	2.2	
28	Clinical trial design in small cell lung cancer: Surrogate endpoints and statistical evolution.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 7087-7087	2.2	
27	Protein inhibitor of activated STAT3 expression in lung cancer. <i>Molecular Oncology</i> , <b>2011</b> , 5, 256-64	7.9	30
26	Phase I Clinical Trials in Patients 80. <i>Journal of Geriatric Oncology</i> , <b>2011</b> , 2, 142-146	3.6	5
25	A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors. <i>Investigational New Drugs</i> , <b>2011</b> , 29, 126-30	4.3	15
24	Temporal evolution of patient characteristics enrolled on phase I trials. <i>Investigational New Drugs</i> , <b>2011</b> , 29, 312-5	4.3	
23	Identification of STAT3-independent regulatory effects for protein inhibitor of activated STAT3 by binding to novel transcription factors. <i>Cancer Biology and Therapy</i> , <b>2011</b> , 12, 139-51	4.6	7
22	Hunting and trapping the vascular endothelial growth factor. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 185-7.2	7.2	11
21	A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. <i>Thyroid</i> , <b>2009</b> , 19, 233-40	6.2	150
20	Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 6006-11	2.2	117
19	The association and nuclear translocation of the PIAS3-STAT3 complex is ligand and time dependent. <i>Molecular Cancer Research</i> , <b>2009</b> , 7, 1854-60	6.6	32
18	A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 3583-90	12.9	84
17	Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer. <i>International Journal of Cancer</i> , <b>2009</b> , 125, 1728-34	7.5	22
16	Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 65, 73-8	3.5	12
15	Ongoing trials with bevacizumab and other antiangiogenic agents in lung cancer. <i>Clinical Lung Cancer</i> , <b>2008</b> , 9 Suppl 2, S71-5	4.9	2
14	Multi-institutional phase I trials of anticancer agents. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1926-31	2.2	23

13	Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab—an Eastern Cooperative Oncology Group Study. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 1407-12	12.9	225
12	SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2. <i>Anti-Cancer Drugs</i> , <b>2008</b> , 19, 9-16	2.4	13
11	Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer. <i>Lung Cancer</i> , <b>2007</b> , 55, 349-55	5.9	47
10	Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy. <i>Lung Cancer</i> , <b>2007</b> , 56, 377-81	5.9	28
9	Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. <i>New England Journal of Medicine</i> , <b>2006</b> , 355, 2542-50	59.2	4760
8	Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer. <i>Investigational New Drugs</i> , <b>2005</b> , 23, 563-7	4.3	8
7	Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 7938-44	12.9	43
6	Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. <i>Molecular Cancer Therapeutics</i> , <b>2004</b> , 3, 459-63	6.1	46
5	Combination chemotherapy with topotecan for non-small cell lung cancer. <i>Lung Cancer</i> , <b>2003</b> , 41 Suppl 4, S23-6	5.9	1
4	A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. <i>Cancer Research</i> , <b>2002</b> , 62, 3408-16	10.1	281
3	Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2001</b> , 47, 141-8	3.5	26
2	Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 2309-18	2.2	30
1	Oral combination chemotherapy in the management of AIDS-related lymphoproliferative malignancies. <i>Drugs</i> , <b>1999</b> , 58 Suppl 3, 99-107	12.1	7